All 158 exposed subjects were included in the safety analysis set and the full analysis set
When initiating Wegovy in pediatric patients aged 12 years and older with type 2 diabetes, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
A lower price tag does not always mean lower quality, but it does mean different quality controls and different levels of regulatory oversight
These symptoms may signal the need for adjustments
For many patients, this can translate into easier training, steadier energy, and better recovery when combined with healthy habits
If weight management or glycemic control is the goal today, semaglutide is the option with an approval, a known supply chain, and an established safety record